Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery

Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery

 

Investigator reports that Imprimis’ combination compounded Tri-Moxi and Pred-Moxi formulations produced equivalent patient outcomes compared to traditional standard of care individual eye drops, while reducing the number of eye drop applications by 50% and increasing patient satisfaction

 

The evaluation of Imprimis’ proprietary Tri-Moxi (triamcinolone acetonide and moxifloxacin hydrochloride) and Pred-Moxi (prednisolone acetate and moxifloxacin hydrochloride) combination eye drop formulations was led by

 

, M.D., Medical Director at the Cleveland Eye Clinic and its affiliated laser center Clear Choice Custom LASIK Center, in order to assess standard follow-up care measurements following LASIK surgery as well as drug quality assurance.  Dr. Wiley concluded that Imprimis’ Tri-Moxi and Pred-Moxi combination eye drop formulations produced equivalent outcomes compared to standard follow-up care measurements observed in traditional post-LASIK eye drop treatments.  Dr. Wiley plans to submit detailed data of the findings for presentation at an upcoming ophthalmology industry meeting.

 

Curated from Imprimis Pharmaceuticals and Cleveland Eye Clinic Announce Positive Findings of Evaluation of LessDrops™ Combination Eye Drop Formulations Following LASIK Surgery